Core Insights - WuXi Biologics has received the 2025 CDMO Leadership Awards in the "Biologics - Global" category, marking its eighth consecutive year of recognition for excellence in various areas [1][2][3] Company Achievements - The company has demonstrated a commitment to advancing integrated technology platforms, significantly shortening the development time for monoclonal antibody projects to 9 months, with a recent autoimmune disease project completed in just 6 months [2] - WuXi Biologics has scaled its manufacturing capacity from 4,000 to 16,000 liters using single-use technology (SUT), achieving a 99% success rate from 2022 to 2024 [2] - The company has maintained a 100% success rate in pre-approval inspections (PAI) and has passed over 40 inspections by global regulatory agencies, including 22 by the FDA and EMA [2] Leadership and Recognition - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the importance of the award as a reflection of the trust from global partners and the dedication of the team [3] - The CDMO Leadership Awards evaluated 210 CDMOs based on third-party research, recognizing top performers in four categories across three service regions [3] Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for biologics [4] - The company employs over 12,000 skilled employees across multiple countries, supporting 817 integrated client projects, including 21 in commercial manufacturing [5] Sustainability Commitment - WuXi Biologics prioritizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [6]

Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Humanetics Corporation (“Humanetics”), an advanced clinical-stage ...

Scinai's CEO, Mr. Amir Reichman, CTO, Dr. Dalit Weinstein-Fischer and Business Development Director, Mr. Solomon Gahtan will be holding meetings during the conference days with: Potential pharma partners in the field of I&I and dermatology interested in co-developing or in-licensing one of Scinai's innovative NanoAbs. Prospective clients of the company's end-to-end biologics CDMO services. Institutional and private investors interested in Scinai's value proposition. Additional interested parties are encou ...

Core Insights - Avid Bioservices, Inc. has launched a new corporate website aimed at enhancing visitor experience for current and prospective customers [1][2][3] Company Overview - Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on biologics, providing a comprehensive range of services including CGMP clinical and commercial manufacturing [4] - The company has over 30 years of experience in producing biologics and offers services such as process development, bulk packaging, and regulatory submissions support [4] Website Features - The new website features an improved user experience with user-friendly navigation, enhanced accessibility, video interaction, and educational resources [2][3] - The tagline "Discover the Avid effect.™" is used to highlight the company's differentiation and position as a trusted biologics CDMO [2] Leadership Perspective - The CEO of Avid emphasized the importance of aligning the online presence with the company's commitment to exceptional quality service and customer satisfaction [3]

TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the “Notice”) to holders of its 7.00% Convertible Senior Notes due 2029 (the “Notes”), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the “I ...

Acquisition Overview - GHO Capital Partners and Ampersand Capital Partners have successfully closed the acquisition of Avid Bioservices, a dedicated biologics Contract Development and Manufacturing Organisation (CDMO), in an all-cash transaction valued at approximately $1.1 billion [1][4][7] - Avid's stockholders will receive $12.50 per share in cash, and the company's common stock will be delisted from Nasdaq [4][7] Company Growth and Capabilities - Avid has experienced significant growth, offering full lifecycle capabilities from concept to commercial supply, with substantial investments in state-of-the-art facilities and expertise in bioprocess optimization, analytical testing, and regulatory compliance [2][9] - The company provides a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support, leveraging over 30 years of experience in producing biologics [9] Strategic Focus of GHO and Ampersand - GHO has considerable expertise in the CDMO sector, focusing on expanding technological capabilities, driving acquisitions, and supporting transatlantic expansion across the CDMO value chain [3][10] - Ampersand Capital Partners, with $3 billion in assets under management, is dedicated to growth-oriented investments in the healthcare sector, leveraging a blend of private equity and operating experience to build value [10] Leadership Insights - GHO's Managing Partners expressed excitement about the acquisition, highlighting Avid's strong foundation for future growth and the potential to unlock the business's full potential [4] - Avid's President and CEO noted that the new ownership will provide access to resources that will accelerate growth and enhance capabilities [4]

Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand’s deep experience in CDMO investing to support Avid’s next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners (“Ampersand”), a private equity firm ...

Group 1 - Avid Bioservices, Inc. has received stockholder approval for its transaction with GHO Capital Partners LLP and Ampersand Capital Partners [1][2] - The company anticipates closing the transaction in the coming days, as all closing conditions have been met and regulatory approvals obtained [2] - Avid Bioservices is a dedicated biologics contract development and manufacturing organization, providing a comprehensive range of services for biotechnology and biopharmaceutical industries [3] Group 2 - The company has over 30 years of experience in producing biologics, offering services that include CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support [3] - Avid's services range from standalone process development projects to full development and manufacturing programs through commercialization [3]

Mails Letter to Stockholders Highlighting the Significant, Immediate and Certain Cash Value the Transaction Delivers to StockholdersTUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has mailed a ...

Core Viewpoint - Avid Bioservices, Inc. has received recommendations from leading independent proxy advisory firms ISS and Glass Lewis to vote "FOR" the proposed transaction with GHO Capital Partners LLP and Ampersand Capital Partners, indicating a favorable outlook for stockholders [1][2]. Company Overview - Avid Bioservices is a dedicated biologics contract development and manufacturing organization (CDMO) that provides high-quality development and manufacturing services to biotechnology and pharmaceutical companies [1][5]. - The company has over 30 years of experience in producing biologics and offers a comprehensive range of services including CGMP clinical and commercial drug substance manufacturing, bulk packaging, and regulatory submissions support [5]. Transaction Details - The transaction with GHO and Ampersand is viewed as providing a premium value for Avid stockholders, with ISS noting that the sales process was thorough and the cash consideration offers liquidity and certainty of value [2]. - The Avid Board of Directors has unanimously recommended that stockholders vote "FOR" the proposed transaction [3]. Advisory Information - Moelis & Company LLC is serving as the exclusive financial advisor to Avid, while Cooley LLP is providing legal counsel [4].